World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
33375
World Ranking
14911
National Ranking
7537

Richard S. Finkel publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard S. Finkel sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 398 publications — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Richard S. Finkel D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard S. Finkel sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Richard S. Finkel is affiliated with St. Jude Children's Research Hospital in the United States. Their research contributions primarily focus on neurogenetic and muscular disorders, with particular emphasis on spinal muscular atrophy (SMA) and related genetic conditions.

Their scholarly work spans the fields of medicine and biochemistry, genetics, and molecular biology. Subfields prominently represented in their publications include genetics, molecular biology, surgery, cellular and molecular neuroscience, and biomedical engineering.

Frequent publication venues for their research include:

  • Neuromuscular Disorders
  • Neurology
  • Journal of Neuromuscular Diseases
  • Brain
  • Annals of Neurology

Key research topics covered in their work are:

  • Neurogenetic and Muscular Disorders Research
  • Congenital Anomalies and Fetal Surgery
  • RNA modifications and cancer
  • Muscle Physiology and Disorders
  • Hereditary Neurological Disorders
  • Cardiac Structural Anomalies and Repair
  • Mechanical Circulatory Support Devices

Frequent co-authors collaborating with Richard S. Finkel include:

  • Eugenio Mercuri
  • John Day
  • Basil T. Darras
  • Francesco Muntoni
  • Darryl C. De Vivo

Notable recent papers authored or co-authored by Richard S. Finkel are:

  • Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial (2021), published in The Lancet Neurology
  • Spinal muscular atrophy (2022), published in Nature Reviews Disease Primers
  • Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial (2022), published in Nature Medicine
  • Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial (2022), published in Nature Medicine
  • Spinal muscular atrophy - insights and challenges in the treatment era (2020), published in Nature Reviews Neurology

Richard S. Finkel's research highlights include gene therapy approaches for SMA and efforts to understand disease mechanisms and treatment challenges across genetic neuromuscular disorders.

Best Publications

  • Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management

    Katharine Bushby;Richard Finkel;David J. Birnkrant;Laura E. Case

  • Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

    Richard S. Finkel;Eugenio Mercuri;Basil T. Darras;Anne M. Connolly

  • Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care

    Katharine Bushby;Richard Finkel;David J. Birnkrant;Laura E. Case

  • Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

    Eugenio Mercuri;Basil T. Darras;Claudia A. Chiriboga;John W. Day

  • Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

    Richard S Finkel;Claudia A Chiriboga;Jiri Vajsar;John W Day

  • Consensus Statement for Standard of Care in Spinal Muscular Atrophy

    Ching H. Wang;Richard S. Finkel;Enrico S. Bertini;Mary Schroth

  • Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care.

    Eugenio Mercuri;Richard S Finkel;Francesco Muntoni;Brunhilde Wirth

  • Agalsidase-Beta Therapy for Advanced Fabry Disease: A Randomized Trial

    Maryam Banikazemi;Jan Bultas;Stephen Waldek;William R. Wilcox

  • Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics.

    Richard S. Finkel;Eugenio Mercuri;Oscar H. Meyer;Anita K. Simonds

  • Observational study of spinal muscular atrophy type I and implications for clinical trials

    Richard S. Finkel;Michael P. McDermott;Petra Kaufmann;Basil T. Darras

  • Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.

    Darryl C. De Vivo;Enrico Bertini;Kathryn J. Swoboda;Wuh-Liang Hwu

  • Ataluren treatment of patients with nonsense mutation dystrophinopathy

    Katharine Bushby;Richard Finkel;Brenda Wong;Richard Barohn

  • An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge.

    Catherine A. Brownstein;Alan H. Beggs;Nils Homer;Barry Merriman

  • Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    Craig M McDonald;Craig Campbell;Ricardo Erazo Torricelli;Richard S Finkel;Richard S Finkel

  • Mutational Spectrum of DMD Mutations in Dystrophinopathy Patients: Application of Modern Diagnostic Techniques to a Large Cohort

    Flanigan Km;Dunn Dm;von Niederhausern A;Soltanzadeh P

  • Natural history of infantile-onset spinal muscular atrophy.

    Stephen J. Kolb;Christopher S. Coffey;Jon W. Yankey;Kristin Krosschell

  • CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis

    V Fridman;B Bundy;M M Reilly;D Pareyson

  • Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.

    John W Day;Richard S Finkel;Claudia A Chiriboga;Anne M Connolly

  • The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability.

    A.M. Glanzman;E. Mazzone;M. Main;M. Pelliccioni

  • Agalsidase-Beta Therapy for Advanced Fabry Disease

    Maryam Banikazemi;Jan Bultas;Stephen Waldek;William R. Wilcox

Frequent Co-Authors

Francesco Muntoni
Francesco Muntoni University College London
Eugenio Mercuri
Eugenio Mercuri Catholic University of the Sacred Heart
Darryl C. De Vivo
Darryl C. De Vivo Columbia University
Craig M. McDonald
Craig M. McDonald University of California, Davis
Jerry R. Mendell
Jerry R. Mendell The Ohio State University
Michael P. McDermott
Michael P. McDermott University of Rochester
Michael E. Shy
Michael E. Shy University of Iowa
Kevin M. Flanigan
Kevin M. Flanigan The Ohio State University
Carsten G. Bönnemann
Carsten G. Bönnemann University of Pennsylvania
Enrico Bertini
Enrico Bertini Bambino Gesù Children's Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare pathways can open doors to rewarding careers for those who may not follow the traditional medical school route. Many prospective students consider nursing as a flexible and in-demand field. If you’re seeking programs with easier entry requirements, you might investigate nursing schools with high acceptance rates. These schools can offer accessible opportunities without compromising the quality of education.

For those interested in the administrative side of healthcare, consider an online healthcare administration degree. Accelerated programs allow you to earn credentials quickly and prepare for management roles within various medical settings.

Practical nursing is another fast-track option. If standardized testing is a barrier, find an LPN program without TEAS test requirements. This can help you start your nursing career sooner.

Additionally, careers in medical administration are increasingly popular. Consider training at one of the best medical billing and coding schools online to gain essential skills for behind-the-scenes healthcare roles, often with flexible schedules and financial aid.

Best Scientists Citing Richard S. Finkel

Trending Scientists

Recently Published Articles